Supplements

Zymeworks Files Preliminary Prospectus Supplements for Offering of Common Shares and Pre-Funded Warrants

British Columbia—Zymeworks Inc. a medical-level biopharmaceutical employer growing multifunctional biotherapeutics, has nowadays filed a preliminary prospectus complement (the “Canadian Supplement”) to its Canadian short shape base shelf prospectus dated March 6, 2019 (the “Base Prospectus”) in reference to an supplying of its commonplace shares and pre-funded warrants to purchase its not unusual shares (the “Offering”). The Canadian Supplement becomes filed with the securities regulatory government in each of the provinces and territories of Canada. A initial prospectus supplement (the “U.S. Supplement,” collectively with the Canadian Supplement, the “Supplements”) changed into additionally filed with the U.S. Securities and Exchange Commission (the “SEC”) as part of a registration assertion on Form S-3, as amended, such as a prospectus which have become effective January 31, 2019 (the “Registration Statement”), pursuant to which the securities may be presented inside the United States.
The Company also expects to supply to the underwriters a 30-day over-allotment option to buy as much as a further 15% of the number of not unusual stocks supplied in the Offering. The Offering is anticipated to be priced in the context of the marketplace, with the final phrases of the Offering to be decided at the time of pricing. There may be no assurance as to whether or not or while the Offering can be finished, or as to the actual size or phrases of the Offering. The closing of the Offering can be a challenge to standard last situations, inclusive of the listing of the commonplace shares at the TSX and NYSE and any required approvals of every alternate. The pre-funded warrants will no longer be listed at the TSX or the NYSE.
The Offering is anticipated to elevate overall gross proceeds of about US$a hundred and fifty.0 million, before deducting underwriting reductions and commissions and predicted imparting fees. The Company intends to use the net proceeds of the Offering (i) to boost up and increase the global development of ZW25 each as a single agent and in mixture with other anti-carcinogens in a ramification of HER2-expressing tumors, which include gastroesophageal, breast and different underserved cancers; (ii) to accelerate and expand the medical improvement of ZW49; (iii) to improve different novel preclinical applications, consisting of the ones involving non-HER2-expressing tumors; and (iv) for widespread corporate functions.
J.P. Morgan Securities, LLC is acting as active ebook-running manager for the Offering. Wells Fargo Securities, LLC, and Stifel, Nicolaus & Company, Incorporated are acting as passive e book-going for walks managers, Raymond James Ltd. Is appearing as co-lead supervisor and Ladenburg Thalmann & Co. Inc. Is performing as co-manager.
The Supplements and the Registration Statement incorporate important distinctive facts about the Offering. A replica of the Canadian Supplement may be discovered on SEDAR at www.Sedar.Com and www.Sec.Gov, and a copy of the U.S. Supplement and the associated Registration Statement can be determined on EDGAR at www.Sec.Gov. Copies of the Supplements can also be acquired from J.P. Morgan Securities, LLC, Attention; Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or through smartphone at (866) 803-9204; Wells Fargo Securities, LLC, Attention; Equity Syndicate Department, 375 Park Avenue, New York, NY 10152, through cellphone at (800) 326-5897, or through email at [email protected]; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by way of phone at (415) 364-2720, or by using e mail at [email protected] Prospective traders ought to study the Supplements and the Registration Statement before making an investment selection.
This information release shall no longer represent a suggestion to promote or the solicitation of a proposal to buy, nor shall there be any sale of those securities in any province, state or jurisdiction wherein such offer, solicitation or sale could be unlawful prior to the registration or qualification below the securities laws of this kind of province, state or jurisdiction.
About Zymeworks Inc.
Zymeworks is a clinical-level biopharmaceutical organization devoted to the development of next-technology multifunctional biotherapeutics. The Company’s suite of healing systems and its absolutely integrated drug improvement engine allow specific engineering of fantastically differentiated product candidates. Zymeworks’ lead medical candidate, ZW25, is a unique Azymetric™ bispecific antibody presently in Phase 2 clinical improvement. The Company’s second clinical candidate, ZW49, is a bispecific antibody-drug conjugate presently in Phase 1 clinical improvement and combines the precise layout and antibody framework of ZW25 with Zymeworks’ proprietary ZymeLink™ cytotoxic payload. Zymeworks is also advancing a deep preclinical pipeline in immuno-oncology and other healing areas. In addition, its healing systems are being leveraged via strategic partnerships with 9 biopharmaceutical companies.
Cautionary Note Regarding forwarding-Looking Statements
This press release consists of “forward-looking statements” inside that means of the U.S. Private Securities Litigation Reform Act of 1995 and “ahead-searching data” within the meaning of Canadian securities laws, or collectively, forward-searching statements. Forward-looking statements on this information release include statements that relate to the Offering, the expected length of the Offering, the granting of the over-allotment alternative, the predicted use of proceeds from the Offering, and other facts that aren’t historical statistics. When used herein, phrases which include “enhance”, “agree with”, “provoke”, “may also”, “plan”, “will”, “estimate”, “continue”, “assume”, “intend”, “anticipate” and similar expressions are meant to discover ahead-looking statements. In addition, any statements or statistics that seek advice from expectancies, ideals, plans, projections, objectives, overall performance or different characterizations of destiny events or situations, inclusive of any underlying assumptions, are forward-looking. All forward-searching statements are based upon Zymeworks’ contemporary expectancies and numerous assumptions. Zymeworks believes there’s a reasonable foundation for its expectancies and beliefs, but they may be inherently uncertain. Zymeworks may not understand its expectations, and its beliefs might not prove correct. Actual results may want to vary materially from those described or implied by using such ahead-searching statements due to various factors, inclusive of, without challenge, marketplace conditions and the elements described beneath “Risk Factors” inside the Base Prospectus, the Registration Statement, the Supplements and Zymeworks’ Quarterly Report on Form 10-Q for the 3 month length ended March 31, 2019 (a replica of which may be obtained at www.Sec.Gov and www.Sedar.Com). Consequently, ahead-searching statements ought to seem entirely as Zymeworks’ current plans, estimates, and ideals. You should now not place undue reliance on ahead-looking statements. Zymeworks cannot guarantee destiny results, occasions, tiers of hobby, performance or achievements. Zymeworks does not adopt and in particular declines, any obligation to update, republish or revise any forward-looking statements to reflect new records, future events or situations, or to reflect the occurrences of unanticipated occasions, except as may be required by using law.

Related Articles

Back to top button